*ST中珠(600568.SH):控股股東所持1.28億股由朗地科技競得
格隆匯11月30日丨*ST中珠(600568.SH)公佈,公司於2020年10月28日披露了《中珠醫療控股股份有限公司關於控股股東所持公司部分股份被司法拍賣的進展公告》,上海中院於2020年10月24日至2020年10月27日在公拍網司法拍賣平台上對“被執行人珠海中珠集團股份有限公司名下1.28億股中珠醫療股票”進行網絡拍賣。經公開競價,競買人深圳市朗地科技發展有限公司(以下簡稱“朗地科技”)以最高應價競得本拍賣標的。
近日,公司收到朗地科技送達的上海中院《執行裁定書》,據《執行裁定書》裁定,解除對上述司法拍賣股份的凍結並歸買受人朗地科技所有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.